Resultats de la cerca - Jake Shortt

Refinar resultats
  1. 1
    Oncogenes in Cell Survival and Cell Death

    Oncogenes in Cell Survival and Cell Death per Jake Shortt, Ricky W. Johnstone

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura

    ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura per Jake Shortt, Danielle H. Oh, Stephen Opat

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  3. 3
    Erratum: A chemical probe toolbox for dissecting the cancer epigenome

    Erratum: A chemical probe toolbox for dissecting the cancer epigenome per Jake Shortt, Christopher J. Ott, Ricky W. Johnstone, James E. Bradner

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

    An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors per Alison C. West, Stephen R. Mattarollo, Jake Shortt, Leonie A. Cluse, Ailsa J. Christiansen, Mark J. Smyth, Ricky W. Johnstone

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

    Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy per Marta Chesi, Geoffrey M. Matthews, Victoria M. Garbitt, Stephen Palmer, Jake Shortt, Marcus Lefebure, A. Keith Stewart, Ricky W. Johnstone, P. Leif Bergsagel

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

    Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma per Geoffrey M. Matthews, Marcus Lefebure, Maria Doyle, Jake Shortt, Jason Ellul, Marta Chesi, K-M Banks, Eva Vidacs, Dorothy Faulkner, Peter Atadja, P. Leif Bergsagel, Ricky W. Johnstone

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

    The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia per Adele Baker, Gareth P. Gregory, Inge Verbrugge, Lev M. Kats, Joshua J. Hilton, Eva Vidacs, Erwin M. Lee, Richard B. Lock, Johannes Zuber, Jake Shortt, Ricky W. Johnstone

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo

    CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo per Gareth P. Gregory, Simon J. Hogg, Lev M. Kats, Eva Vidacs, Adele J. Baker, Omer Gilan, Marcus Lefebure, Benjamin P. Martin, Mark A. Dawson, Ricky W. Johnstone, Jake Shortt

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  9. 9
    Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

    Bortezomib-based antibody depletion for refractory autoimmune hematological diseases per Sumita Ratnasingam, Patricia Walker, Huy Tran, Zane Kaplan, James D. McFadyen, Huyen Tran, Tse-Chieh Teh, Shaun Fleming, John Catalano, Sanjeev Chunilal, Anna Johnston, Stephen Opat, Jake Shortt

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

    Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma per Maciej Tatarczuch, Mark Waltham, Jake Shortt, Galina Polekhina, Eliza A. Hawkes, Shir‐Jing Ho, Judith Trotman, Daniella Brasacchio, Melannie Co, Jessica Li, Vanitha Ramakrishnan, Karin Dunne, Stephen Opat, Gareth P. Gregory

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Manipulation of B-cell responses with histone deacetylase inhibitors

    Manipulation of B-cell responses with histone deacetylase inhibitors per Michaela Waibel, Ailsa J. Christiansen, Margaret L. Hibbs, Jake Shortt, Sarah A. Jones, Ian Simpson, Amanda Light, Kristy O’Donnell, Eric F. Morand, David M. Tarlinton, Ricky W. Johnstone, Edwin D. Hawkins

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

    BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members per Simon J. Hogg, Andrea Newbold, Stephin J. Vervoort, Leonie A. Cluse, Benjamin P. Martin, Gareth P. Gregory, Marcus Lefebure, Eva Vidacs, Richard W. Tothill, James E. Bradner, Jake Shortt, Ricky W. Johnstone

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors

    Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors per Michael Bots, Inge Verbrugge, Benjamin P. Martin, Jessica M. Salmon, Margherita Ghisi, Adele Baker, Kym L. Stanley, Jake Shortt, Gert J. Ossenkoppele, Johannes Zuber, Amy Rappaport, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus

    Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus per Baolong Pan, Simon J. Mountford, Maki Kiso, Danielle E. Anderson, Georgina Papadakis, Kate E. Jarman, Danielle Tilmanis, Belinda Maher, Thomas Tran, Jake Shortt, Seiya Yamayoshi, Yoshihiro Kawaoka, Philip E. Thompson, Sam Greenall, Nadia Warner

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd

    Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd per Timothy P. Hughes, Eduardo Munhoz, Marco Aurélio Salvino, Tee Chuan Ong, Alaa Elhaddad, Jake Shortt, Hang Quach, Carolina Pavlovsky, Vernon Louw, Lee‐Yung Shih, Anna Turkina, Luis Meillón, Yu Jin, Sandip Acharya, Darshan Dalal, Jeffrey H. Lipton

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma

    NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma per Stephen R. Mattarollo, Alison C. West, Kim Steegh, Helene Duret, Christophe Paget, Ben P. Martin, Geoffrey M. Matthews, Jake Shortt, Marta Chesi, P. Leif Bergsagel, Michael Bots, Johannes Zuber, Scott W. Lowe, Ricky W. Johnstone, Mark J. Smyth

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

    A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis per Kristen Pettit, Aaron T. Gerds, Abdulraheem Yacoub, Justin M. Watts, Maciej Tartaczuch, Terrence Bradley, Jake Shortt, William Stevenson, Natasha Joan Curtin, James M. Rossetti, Kate Burbury, Georges Natsoulis, Amber Jones, Moshe Talpaz, Jennifer Peppe, David M. Ross, Hugh Young Rienhoff

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas

    Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas per Jake Shortt, Benjamin P. Martin, Andrea Newbold, Katherine M. Hannan, Jennifer R. Devlin, Adele J. Baker, Rachael Ralli, Carleen Cullinane, Clemens A. Schmitt, Maurice Reimann, Michael N. Hall, Meaghan Wall, Ross D. Hannan, Richard B. Pearson, Grant A. McArthur, Ricky W. Johnstone

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

    Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma per Jennifer R. Devlin, Katherine M. Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J. George, Jake Shortt, Megan J. Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O’Brien, Ricky W. Johnstone, Grant A. McArthur, Ross D. Hannan, Richard B. Pearson

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

    BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 per Simon J. Hogg, Stephin J. Vervoort, Sumit Deswal, Christopher J. Ott, Jason Li, Leonie A. Cluse, Paul A. Beavis, Phillip K. Darcy, Benjamin P. Martin, Andrew Spencer, Anna K. Traunbauer, Irina Sadovnik, Karin Bauer, Peter Valent, James E. Bradner, Johannes Zuber, Jake Shortt, Ricky W. Johnstone

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: